Reply  by Kern, Morton J.
A
T
B
A
c
m
t
p
l
t
a
r
s
C
V
C
t
b
s
o
m
I
T
c
a
w
p
m
b
t
e
t
p
i
r
s
h
t
a
o
u
c
r
i
a
T
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 3 , N O . 2 , 2 0 1 0
© 2 0 1 0 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 1 0 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C .LETTERS TO THE EDITOR
r
a
i
p
b
e
p
c
p
s
*
*
5
A
E
R
1
2
3
4
R
I
h
t
T
s
r
e
g
c
a
t
w
a
tll Roads (Even Those Less
raveled) Lead to Rome
enefits of Transradial Coronary Interventions
s he walked off the table following a transradial percutaneous
oronary intervention (TRPCI), a morbidly obese patient asked
e if the route from the wrist to the heart was more direct than
hat from the groin. He had reached this conclusion because his
revious transfemoral procedure by another physician was pro-
onged and resulted in a large retroperitoneal hematoma, necessi-
ating transfusion and protracted hospitalization. He was amazed
t the ease and speed with which the TRPCI was performed. I
eplied that all roads lead to Rome; some are just easier to find and
afer than others.
I applaud Dr. Kern’s recommendations in his editorial “Cardiac
atheterization on the Road Less Traveled: Navigating the Radial
ersus Femoral Debate?” from the previous issue of JACC:
ardiovascular Interventions (1), that the seasoned interventionalist
o be well-versed in both access sites. The virtual elimination of
leeding risk associated with TRPCI is undeniable, even by the
keptics. As the obesity epidemic appears to spread unchecked in
ur nation, one can only expect that physicians will encounter
ore patients similar to the one in the preceding example.
ronically, we trail other nations in acceptance of this technique.
his patient is illustrative of the size paradox for TRPCI. In most
ases, obese patients are actually excellent candidates for this
pproach, as they have large radial arteries, with robust pulses.
Immediate ambulation is a great benefit for individuals afflicted
ith back conditions. Patients not infrequently consider the
ost-procedural groin compression and recuperative bed rest as the
ost uncomfortable aspects of the procedure (2). As demonstrated
y Cooper et al. (3), all quality-of-life indices favor transradial over
ransfemoral access. A secondary, perhaps less appreciated, differ-
nce is the intangible loss of privacy associated with instrumenta-
ion of the very personal groin area. When questioned, many
atients thus perceive the transradial approach as somehow less
nvasive.
Another patient, who had undergone uncomplicated transfemo-
al stenting years ago, developed an inflammatory cyst at the access
ite after a subsequent TRPCI. This phenomenon is a rare
ypersensitivity reaction to the hydrophilic coating on certain
ransradial sheaths and requires only lancing and application of
ntibiotic ointment. Upon hearing my apology for the adverse
ccurrence, the patient simply inquired: “Doc, can you please still
se my wrist next time?” He preferred a (minor) transradial
omplication over an uncomplicated transfemoral procedure.
Importantly, elective PCI in the U.S. is now defined and
eimbursed by Medicare as an outpatient procedure. TRPCI is
deally suited for early ambulation and discharge, thus allowing
lignment of practice with payment. In the STRIDE (Same-day
ransRadial Intervention and Discharge Evaluation) trial, we hetrospectively demonstrated the potential safety and feasibility of
mbulatory discharge following TRPCI (4).
Regarding concerns over radiation exposure, simple setup mod-
fications can easily remedy the situation. By positioning the arm
arallel, rather than perpendicular, to the body, the wrist is actually
elow the level of the groin. Moreover, the addition of an
xtension tubing allows the operator to stand at the level of the
atient’s foot during injections.
Clearly, interventionalists, like travelers, will differ in their
hoice of routes to a common destination. Nonetheless, it may be
referable to have access to both the larger freeway as well as the
maller, less travelled but perhaps safer, back road.
Jack P. Chen, MD
Saint Joseph’s Heart and Vascular Institute
670 Peachtree Dunwoody Road, #880
tlanta, Georgia 30342
-mail: jchen@sjha.org
doi:10.1016/j.jcin.2009.10.027
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eply
thank Dr. Chen for his interest in my editorial (1) and for again
ighlighting the undeniable facts about the superiority of the
ransradial approach relative to the U.S. standard of femoral access.
he issue is not whether radial access is better but why has it taken
o long to be adopted in this country and what can we do about it?
As a recently converted sinner, I am intimately familiar with the
ationale to delay adoption but once on the “Radial First” road, my
xperience and that of my patients confirms it is the right road. I
ained some insight from a recent conversation with a young
atheterization lab director in Springfield, Massachusetts, when
sked why he was not teaching radial technique to the fellows in
raining. The same litany of excuses was chagrinly provided. “It
as the way I was trained” was the first excuse. If we kept to that
pproach, I would still be doing cut-downs on the brachial artery.
I believe it is the duty of every interventionalist in charge of
raining fellows to take this challenge and duty to their patients to
eart. I am sure Dr. Chen would agree that we should use this new
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Letters to the Editor260omentum, driven by the extensive datasets on better radial access
utcomes to encourage the next generation of interventionalists to
tep to the front of the world’s stage in patient care.
Morton J. Kern, MD
University of California, Irvine
uilding 53, Route 81, Room 100
01 The City Drive
range, California 92868
-mail: mkern@uci.edu
doi:10.1016/j.jcin.2009.11.011
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henotypes, Genotypes, and the
p21 Locus for Prediction of
ardiovascular Events
would like to commend Hoppmann et al. (1) for their thorough
nd well-executed paper. In this regard, I agree with the editorial
y Horne and Anderson (2) that discusses the importance of the
oppmann et al. (1) study. Thoughtfully executed prospective
tudies that attempt to clinically examine genomic data first
dentified in genome-wide association studies are at a premium.
Other remarks in the editorial by Horne and Anderson (2) are
source of disagreement. First, the authors make the argument
hat because replications of the 9p21 single nucleotide polymor-
hisms (SNPs) have been done in populations that suffer from
oth documented coronary artery disease (CAD) and myocardial
nfarction (MI), these individual phenotypes—when grouped to-
ether—confound the type of risk (phenotype) that can be
ttributed to these genetic factors. Although their argument is
nderstood, it is important to point out that on the basis of
xperience, these genetic markers are statistically significant in
oth subpopulations to sometimes nearly equal extent. These data
re sometimes not shown in final reports and are only rarely shown
n supplemental data. The authors then attempt to differentiate the
athogenesis of CAD and that of MI as 2 distinct entities, which
urther precludes attribution of genetic risk to either of those 2
henotypes individually. It is difficult to assume that the well-
nown progression of CAD to MI (barring less usual suspects such
s spasm or dissection) can be so thoroughly extricated from each
ther as to invalidate the dozens of studies that have replicated the
p21 locus as a risk marker for CAD and MI.
The authors then make the argument that because the study by
oppmann et al. (1) finds there to be a negative association
etween restenosis and these genomic markers, restenosis must be idistinct pathophysiologic entity from CAD because it is not
driven” by genetic factors at 9p21.3. Though this might be the
ase as evidenced by much work in cell biology and immunology,
n assumption based on 1 prospective clinical study that examined
SNPs is difficult to accept. Additionally, it should be noted that
he 4 SNPs tested by Hoppmann et al. (1) are not the most
requently validated SNPs for 9p21 but rather an amalgam of
NPs from different studies that first identified the variants. This
s possibly due to the initiation of the 3-year prospective study
efore replications of the more popular variants in better-
haracterized populations.
It is certainly necessary to temper our enthusiasm for direct-to-
onsumer genetic testing until these markers can be better under-
tood, a point of agreement with Horne and Anderson (2). In the
nterim, we should encourage more studies such as the one
resented by Hoppmann et al. (1) and continue our emphasis on
reventative cardiovascular medicine.
Kalil G. Abdullah, BS
Cleveland Clinic
erner College of Medicine
oward Hughes Medical Institute
ffice of Grants and Special Programs
Cloister Court
ethesda, Maryland 20814
-mail: abdullk@ccf.org
doi:10.1016/j.jcin.2009.12.005
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eply
e would like to thank Dr. Abdullah for the remarks regarding
ur editorial (1). We appreciate the subtleties of our assertions and
cknowledge that the important biological distinctions among
yocardial infarction (MI), coronary artery disease (CAD), and
estenosis might be unfamiliar. We appreciate the opportunity to
larify our arguments.
It was not our intent to claim that prior studies associating
p21.3 with MI risk are invalid but to say that some erroneous
onclusions about pathophysiological implications for coronary
eart disease were drawn from those landmark studies. Because
estenosis is a different process than CAD (2), our intent also was
o note that 9p21.3 is not involved in its distinctive pathophysi-
logy (1).
A major component of our argument is, in fact, that 9p21.3
ingle nucleotide polymorphisms “are statistically significant in
oth subpopulations to sometimes nearly the same extent.” To
llustrate, consider 1 European study that showed a similar effect
